|Limited liability partnership|
|Headquarters||London, United Kingdom|
|Dominic Slade (Managing Partner),
Ian Cash (Partner),
Frits Prakke (Partner)
|Products||Investments, private equity funds|
|Total assets||£1500 million|
Alchemy Partners is a British private equity firm, which specialises in investing in distressed and undervalued or underperforming businesses and other special situations through debt and equity throughout Europe. Before launching dedicated distressed vehicles, it invested over £1bn of equity in over 80 transactions.
Alchemy was founded in 1997 by Martin Bolland and Jon Moulton. Before launching dedicated distressed vehicles, it invested over £1bn of equity in over 80 transactions. Notable transactions included Four Seasons Health Care, Alcentra and Phoenix IT.
Alchemy came to public notice in 1999, when it was negotiating to buy Rover Group from BMW; its advisory board members included former Rover MD Kevin Morley. After public protests, the discussions were abandoned when the government imposed additional conditions to the transaction.
Alchemy launched its first distressed debt fund, Alchemy Special Opportunities, in 2006 with a final close of £300m.
Moulton resigned from Alchemy in September 2009, saying that he disagreed with plans by other partners to turn Alchemy into a specialist financial services firm.
Alchemy raised £500m for the second distressed debt fund in 2010. Alchemy is currently investing from its £600m Alchemy Special Opportunities Fund III, raised in March 2014. The Funds invest in the debt and equity of public and private companies in the UK and continental Europe. Funding is provided by a large number of blue-chip investors including major banks, pension funds, fund-of-funds, university endowments and high-net-worth individuals. Today the firm manages/advises over £1.5bn.
- Alchemy Partners website
- Jon Moulton, founder, Alchemy Partners: Dicing with the debt meister. The Independent, 29 October 2006
- BBC News, 28 April 2000
- "Alchemy fund eyes distressed companies". Financial Times. April 4, 2011.